We calculated the rates for perioperative mortality and fatal pulmonary embolism (PE) after primary total hip replacement in a single UK health region, using a regional arthroplasty register and the tracing service of the Office of National Statistics. The routine use of chemical thromboprophylaxis for primary THR is still controversial. The issue should be addressed by an appropriate randomised, prospective study using overall mortality and fatal PE rate as the main outcome measures, but the feasibility of such a study is questioned. [Br] 1997;79-B:896-9. Received 10 February 1997; Accepted after revision 18 July 1997 Death from pulmonary embolism (PE) is a recognised complication of total hip replacement (THR), but the exact prevalence is unknown. Historical reports suggested a fatal PE rate of 2.3% to 3.4%, 1,2 but more recent series have shown that the overall mortality after THR is only of the order of 1%. 3-5 Two recent papers have reported fatal PE rates of 0.34% 6 and 0.38%. 7 Both were from single centres, one a specialist orthopaedic unit and one a large district general hospital, neither of which used routine chemical thromboprophylaxis. Both series included a proportion of patients who had revision THR and may not therefore be truly representative. A meta-analysis of all studies on THR which included data on death or fatal PE indicated that the rates of both had fallen since the 1960s and that the current death rate was 0.3% to 0.4% with a fatal PE rate of 0.1% to 0.2%.
Death from pulmonary embolism (PE) is a recognised complication of total hip replacement (THR), but the exact prevalence is unknown. Historical reports suggested a fatal PE rate of 2.3% to 3.4%, 1,2 but more recent series have shown that the overall mortality after THR is only of the order of 1%. [3] [4] [5] Two recent papers have reported fatal PE rates of 0.34% 6 and 0.38%. 7 Both were from single centres, one a specialist orthopaedic unit and one a large district general hospital, neither of which used routine chemical thromboprophylaxis. Both series included a proportion of patients who had revision THR and may not therefore be truly representative. A meta-analysis of all studies on THR which included data on death or fatal PE indicated that the rates of both had fallen since the 1960s and that the current death rate was 0.3% to 0.4% with a fatal PE rate of 0.1% to 0.2%. 8 The main controversy concerns the use of chemical thromboprophylaxis and the prevention of fatal PE. The earlier high rates for fatal PE are sometimes quoted to support the use of chemical thromboprophylaxis; 9 claims have been made that failure to use such prophylaxis may be deemed negligent. 10 A Working Party of the Royal College of Surgeons on venous thromboprophylaxis 11 felt that the issue was unresolved, and that "each patient should have a risk assessment and be managed according to the surgeon's current practice". Our prospective, observational study assessed the rate of fatal PE in a large cohort of consecutive primary THRs performed in a single UK health region, providing a descriptive analysis of the use of chemical thromboprophylaxis in the cohort.
PATIENTS AND METHODS
We studied all patients having a primary THR in 1990, as registered with the Trent Regional Arthroplasty Study (TRAS). This is the only regional arthroplasty register in England which, since the beginning of 1990, has recorded prospectively all primary total hip and knee replacements performed throughout the Trent region. Patients are entered at the time of the operation by the surgeon who completes a standard form recording demographic, medical and operative details including the use and type of chemical thromboprophylaxis. This is then returned to the study centre and the data are validated by a peripatetic clerk who checks theatre records, consultant records and the patient administration system of each hospital, to ensure that no data are lost.
We began a detailed five-year assessment of the 1990 primary THRs in 1995, attempting to contact all patients. Details of those missing were supplied by a tracing service of the Office of National Statistics and the 1995 status of all the cohort is known. For patients who had died, the date, place, and certified cause of death are known, with details of all postmortem examinations which were performed.
During 1990, there were 2111 consecutive primary THRs in 2036 patients, under the care of 66 consultants, in 19 national health service and seven private hospitals. Twentyone patients had a bilateral procedure and another 54 had both hips replaced during the year under study. A total of 2090 separate primary procedures was performed.
The medical records were scrutinised to validate data supplied to TRAS and to record details of the past medical history, the drug history, the operation and the postoperative period. We analysed data to compare groups of patients and the use of chemical thromboprophylaxis by logistic regression models and adjusted odds ratios using the SPSS version 7.0 for windows (SPSS Inc, Chicago, Illinois). The 95% confidence intervals (CI) have been given where appropriate, using the formula for the standard error of a proportion based on the normal approximation of the Poisson distribution. 12 
RESULTS
Chemical thromboprophylaxis. Information on the use or avoidance of chemical thromboprophylaxis was available for 1893 of cases and not known for 218. A comparison of these two groups using independent univariate logistic regression analysis showed no significant differences for age (≤ 60, ≥ 61 years; p = 0.620), gender (p = 0.234) or primary diagnosis (osteoarthritis, rheumatoid arthritis, other; p = 0.71).
Of the 1893 arthroplasties for which the use or otherwise of chemical thromboprophylaxis was known, 1226 (64.8%) received some form of agent and 667 (35.2%) had none. Comparison of these two groups using independent univariate logistic regression analysis showed no significant differences for gender (p = 0.705) or primary diagnosis (p = 0.335). There was a statistically significant difference for the age of the patients (p = 0.002): a greater proportion of the younger patients received chemical thromboprophylaxis (71% ≤ 60 years v 62% ≥ 61 years) ( Table I) .
Full medical and thromboprophylaxis data were available for 1873 THRs and this was analysed to assess the effect of certain risk factors (cardiac disease, varicose veins, malignancy and thromboembolic disease), on the chemical thromboprophylaxis as documented in the preoperative notes (Table II) . The only one which led to a significantly greater use of chemical thromboprophylaxis was a previous history of thromboembolic disease (p = 0.0001), but this was relatively rare, applying to only 56 cases. Stepwise multivariate logistic regression analysis confirmed that finding (p = 0.0001) and showed that age (p = 0.0012) was the only other variable which differed significantly between the groups that did and did not receive chemical thromboprophylaxis. The adjusted odds ratio for a previous history of thromboembolic disease was 3.261 (95% CI 1.819 to 5.844) and for age 1.21 (95% CI 1.078 to 1.358). When adjusted for other factors including age, a patient with a previous history of thromboembolic disease was over three times more likely to receive chemical thromboprophylaxis. Mortality and fatal PE rate. Within 42 days of surgery, 19 patients (Table III) had died (0.91% of procedures, 95% CI 0.55 to 1.42). Ten of these had received chemical thromboprophylaxis, seven had received none and for two patients the data were missing. The mortality rate with chemical thromboprophylaxis was 10/1226 (0.82%, 95% CI 0.39 to 1.50) and without it 7/667 (1.05%, 95% CI 0.42 to 2.16). There was no significant difference between these mortality rates (one-tailed Fisher's exact test, p = 0.39).
Four deaths due to PE were confirmed on postmortem examination (Table IV) . Two of these were during the inpatient stay, one was at home and one followed admission to another hospital. Three of these patients had received chemical thromboprophylaxis (two subcutaneous heparin and one aspirin). Only one had a significant medical history with atrial fibrillation and anaemia, treated with digoxin and diuretics; this patient became dehydrated soon after the (Table III) . Six patients did not have postmortem examinations and it is possible that these deaths were due to PE (Table I) . If all six were due to PE the fatal PE rate would have been 10/2090 (0.48%, 95% CI 0.23 to 0.88).
To ensure that no late fatal PEs had been overlooked we scrutinised all deaths up to six months after operation: no additional cases of PE were recorded.
DISCUSSION
Our results, from a large number of primary THRs at a number of hospitals by many different surgeons, confirm recent published data which have shown the overall perioperative mortality to be of the order of 1%, 4 but are higher than the 0.3% to 0.4% derived from meta-analysis. 8 The rate of proven fatal PE of 0.19% (95% CI 0.05 to 0.49) is similar to the 0.34% (95% CI 0.09 to 0.88) reported by Warwick et al 6 and the 0.38% reported by Mcgrath et al 7 and matches the 0.1% to 0.2% calculated by meta-analysis. 8 The true fatal PE rate in this cohort may be as high as 0.48% (95% CI 0.23 to 0.88); this emphasises the need for postmortem examination after perioperative deaths. The two fatal PE rates reported by Warwick et al 6 and
Mcgrath et al 7 were for patients who had received no routine chemical thromboprophylaxis, although in both series particularly high-risk patients had received some form of prophylaxis. Our series suggests that the use of chemical thromboprophylaxis had little effect on either overall mortality or the rate of fatal PE. We recognise that treatment was not randomised, but the groups of patients which did or did not receive chemical prophylaxis were similar, with similar risk factors, except for the few who had a previous history of thromboembolic disease. We found that younger patients were more likely to receive chemical prophylaxis, which was unexpected as these patients are generally fitter and more active. 10 it is not negligent to withhold such agents. This view was agreed by 36% of a sample of members of the British Orthopaedic Association; they considered that low-dose anticoagulants were not a medicolegal necessity in routine THR. 15 We appreciate the considerable limitations of our data, but feel that they provide an accurate observation of a large mixed cohort of primary THRs in a modern setting. The low overall mortality and rate for fatal PE are encouraging. The improvement which may be gained with the routine use of chemical thromboprophylaxis can only be addressed by an appropriately designed randomised study, 6, 16 but the rare nature of the events means that the size of such trials may make them unfeasible. Based on our data, a relative risk reduction of 25% in the 42-day mortality of 1% may be expected with chemical thromboprophylaxis. A randomised controlled trial with an 80% power to demonstrate such a difference as statistically significant at the 5% level would require over 45 000 patients. If fatal PE were to be used as the endpoint, over 67 000 patients would be required.
